A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany

被引：0
|
作者：
Maureen Watt
Charles McCrea
Sukhvinder Johal
John Posnett
Jameel Nazir
机构：
[1] Astellas EMEA,
[2] PAREXEL Access Consulting,undefined
[3] Astellas Pharma Europe Ltd.,undefined
来源：
Infection | 2016年 / 44卷
关键词：
Cost-effectiveness; Budget impact; Fidaxomicin; Vancomycin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：599 / 606
页数：7
相关论文
共 50 条
  • [41] Cost-effectiveness and budget impact of the management of uncomplicated urinary tract infection by community pharmacists
    Sanyal, Chiranjeev
    Husereau, Donald R.
    Beahm, Nathan P.
    Smyth, Daniel
    Tsuyuki, Ross T.
    BMC HEALTH SERVICES RESEARCH, 2019, 19 (1) : 499
  • [42] Cost-effectiveness and budget impact of the management of uncomplicated urinary tract infection by community pharmacists
    Chiranjeev Sanyal
    Donald R. Husereau
    Nathan P. Beahm
    Daniel Smyth
    Ross T. Tsuyuki
    BMC Health Services Research, 19
  • [43] Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer
    Attard, C. L.
    Brown, S.
    Alloul, K.
    Moore, M. J.
    CURRENT ONCOLOGY, 2014, 21 (01) : E41 - E51
  • [44] Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma
    Zhang, Pengfei
    Yang, Yu
    Wen, Feng
    He, Xiaofeng
    Tang, Ruilei
    Du, Zedong
    Zhou, Jing
    Zhang, Jian
    Li, Qiu
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 27 (07) : 853 - 859
  • [45] Cost-effectiveness and budget impact analysis of peritoneal dialysis and haemodialysis in South Africa
    Thsehla, Evelyn
    Boachie, Micheal Kofi
    Goldstein, Susan
    BMC HEALTH SERVICES RESEARCH, 2025, 25 (01)
  • [46] Pharmacoeconomic profile of Paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma - A lifetime cost-effectiveness analysis
    Messori, A
    Trippoli, S
    Becagli, P
    Tendi, E
    CANCER, 1996, 78 (11) : 2366 - 2373
  • [47] Cost-Effectiveness of Ibrutinib as First-line Treatment for Older Patients With Chronic Lymphocytic Leukemia in Iran
    Fariman, Soroush
    Nasab, Fatemeh Momeni
    Faraji, Hoda
    Afzali, Monireh
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 38 : 93 - 100
  • [48] Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
    Pei, Zhengda
    Xiao, Ningping
    Yang, Pei
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [49] Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis
    Rachel Harrington
    Edward Lee
    Hongbo Yang
    Jin Wei
    Andrew Messali
    Nkechi Azie
    Eric Q. Wu
    James Spalding
    Advances in Therapy, 2017, 34 : 207 - 220
  • [50] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Youwen Zhu
    Kun Liu
    Dong Ding
    Yangying Zhou
    Libo Peng
    Advances in Therapy, 2022, 39 : 2614 - 2629
12345